公司概覽
業務類別 Biotechnology
業務概覽 Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
公司地址 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
電話號碼 +1 650 260-7120
傳真號碼 --
公司網頁 https://www.iovance.com
員工數量 975
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Igor P. Bilinsky, PhD Chief Operating Officer 美元 551.24K 28/04/2025
Mr. Daniel Gordon Kirby Chief Commercial Officer -- 28/04/2025
Dr. Frederick G. Vogt, J.D. Director, General Counsel, Interim Chief Executive Officer and President 美元 730.06K 24/02/2026
Ms. Corleen M. Roche Chief Financial Officer and Principal Accounting Officer -- 24/02/2026
Dr. Friedrich Graf Finckenstein, M.D. Chief Medical Officer 美元 612.11K 28/04/2025
Dr. Raj K. Puri, M.D. Chief Regulatory Officer -- 28/04/2025
Mr. Matthew Rosinack Senior Vice President, Finance -- 15/07/2025
 
董事會成員
董事會 職務 更新日期
Dr. Michael Weiser,M.D.,PhD Independent Director 24/02/2026
Mr. Ryan D. Maynard Independent Director 24/02/2026
Dr. Athena Countouriotis, M.D. Independent Director 24/02/2026
Mr. Wayne P. Rothbaum Independent Director 24/02/2026
Dr. Iain D. Dukes, D.Phil. Non-Executive Chairman of the Board 24/02/2026
Dr. Frederick G. Vogt, J.D. Director, General Counsel, Interim Chief Executive Officer and President 24/02/2026
Ms. Wendy L. Yarno, M.B.A. Independent Director 24/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:05)
代號 名稱 佔比% 持有日期
IWViShares Russell 3000 ETF0.02%28/02/2026
GINNGoldman Sachs Innovate Equity ETF0.01%27/02/2026
ISCViShares Morningstar Small-Cap Value ETF0.01%28/02/2026
TECBiShares US Tech Breakthrough Mltsctr ETF0.01%28/02/2026
AVUSAvantis US Equity ETF0.01%28/02/2026
QQQSInvesco NASDAQ Future Gen 200 ETF0.01%27/02/2026
VTHRVanguard Russell 3000 ETF0.01%31/01/2026
IBBQInvesco Nasdaq Biotechnology ETF0.01%27/02/2026
WSMLiShares MSCI World Small-Cap ETF0.005%28/02/2026
UWMProShares Ultra Russell20000.005%27/02/2026
URTYProShares UltraPro Russell20000.005%27/02/2026
BIBProShares Ultra Nasdaq Biotechnology0.004%27/02/2026
ITWOProShares Russell 2000 High Income ETF0.003%27/02/2026
DXUVDimensional US Vector Equity ETF0.003%27/02/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.003%28/02/2026
RFLRInnovator U.S. Small Cp Mgd Flr ETF0.003%25/02/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.003%27/02/2026
ISCBiShares Morningstar Small-Cap ETF0.003%28/02/2026
WDNAWisdomTree BioRevolution ETF0.001%27/02/2026
AVTMAvantis Total Equity Markets ETF0.0003%28/02/2026
  1   2    3  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.